Quince Therapeutics Posts $35.9M Q1 Profit, Reversing Prior Going Concern Doubts
QNCX sits 57% above its 52-week low of $0.8.
Summary
Quince Therapeutics reported a significant financial turnaround in Q1 2026, posting a net income of $35.9 million and diluted EPS of $2.88. This marks a dramatic swing from a net loss of $15.0 million in the prior year's quarter. The profitability comes after the company halted development of its lead drug, eDSP, following a Phase 3 trial failure, leading to substantial reductions in R&D and trial costs. This positive financial performance directly addresses the 'going concern' warning issued in the company's recent 10-K filing on April 10, which had raised doubts about its long-term viability. For traders, this unexpected profitability fundamentally alters the risk profile and investment thesis for the micro-cap company. Investors will now watch for updates on the company's strategic review, including its pursuit of a potential reverse merger and efforts to secure future financing.
At the time of this announcement, QNCX was trading at $1.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.2M. The 52-week trading range was $0.80 to $45.50. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.